Centinel Spine has received the US Food and Drug Administration (FDA) approval for the manufacturing transfer of the prodisc C Cervical Total Disc Replacement and prodisc L Lumbar Total Disc Replacement systems to new strategic vendors.

The company obtained the approval following an extensive two-year process, involving FDA inspection audits at its prodisc manufacturing sites along with the approval of a PMA supplement by the agency.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

According to the company, the approval will enable it to better manage its prodisc supply chain and associated costs.

Centinel Spine CEO Steve Murray said: “This approval is a major achievement by the company, thanks to a complete team effort by many involved.

“The team executed a well-designed plan that included three FDA facility audits, resulting in zero non-conformances or observations. The approval provides the company with control of prodisc manufacturing as we continue to advance both the prodisc cervical and prodisc lumbar systems.”

The company has a good presence in anterior column reconstruction since the acquisition of the prodisc Total Disc Replacement technology platform in 2017.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Centinel Spine is considered to be the only company with FDA-approved cervical and lumbar total disc replacement devices.

The company recently obtained FDA approval for two-level indications for the prodisc L Lumbar Total Disc Replacement system.

It has also initiated clinical trial comparing the prodisc C Vivo and prodisc C SK devices with an approved cervical TDR product as a control to validate their safety and effectiveness in an FDA IDE study.

The company started its operations in 2008 through the merger-acquisition of Raymedica and Surgicraft medical companies.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact